Takeda Oncology | Leading Cancer Treatment Innovation

A person in a lab coat holding a pipette

Decades of Leadership in Oncology

About Takeda Oncology

Recent Oncology News

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 5, 2026

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 6, 2025

Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Generation Investigational Oncology Medicines

December 4, 2025

Takeda Unveils Pioneering Advances in Hematologic Cancers and Rare Blood Disorders at the 67th American Society of Hematology (ASH) Annual Meeting

November 3, 2025

At Takeda, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.

Better Health, Brighter Future

A group of people in lab coats looking through microscopes

Our Medicines

We're committed to advancing treatment options that enhance & extend the lives of people living with cancer.

FIND OUT MORE

A pipette dropping liquid into a test tube

Oncology Pipeline

Our R&D efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers.

FIND OUT MORE

Two people smiling

Patient Advocacy & Support

We're committed to helping people living with cancer navigate their journey – from diagnosis to survivorship.

FIND OUT MORE

Connect with Us

Contact Takeda Oncology for resources, information, or support.